About Us

SonoPlot designs and sells Microplotter® materials dispensing systems for drawing features as small as 10 to 20 microns. Our patented ultrasonic dispensing technology enables true contiguous lines for superior conductive traces and enables the deposition of a wide range of materials, including solutions containing graphene, carbon nanotubes, nanoparticles, and polymers. This technology allows the Microplotter® to print inks with viscosities up to 450 cP without the hassle of tuning them to the printer. Integrated digital video and precise positioning allow for accurate alignment and dispensing on substrates. The Microplotter® systems provide unparalleled price per capability in the market.


Management

Brad Larson, Ph.D., Co-founder & CEO
Brad Larson has over 15 years of experience in engineering, materials science and software development. Brad holds six patents in the area of fluid deposition and cold plasma treatment and developed the technology that SonoPlot is based upon.

He is the author of the GPUImage open source image processing framework, in use by thousands of iOS and Mac applications. His open source Molecules application was one of the first applications to launch with the iPhone App Store in 2008, has been downloaded over 3.5 million times, and has been used in classrooms across the world.

He and Pete Johnson direct the operations of Perceptual Labs, a SonoPlot spin-off that applies machine vision technology to mobile and low-power computers.

Brad earned a bachelor's degree in chemical engineering from the Rose Hulman Institute of Technology and a master's and doctoral degrees in Materials Science from the University of Wisconsin-Madison.

Pete Johnson, Director
Pete Johnson has over 20 years of sales, marketing and technical experience in rapid-growth technology companies. Pete is currently VP of Business Development at zSpace, a leading virtual reality company. Previously, Pete was Director of Worldwide Marketing and Strategy for Xpedion Design Systems, acquired by Agilent Technologies. Before Xpedion, Pete held various sales and marketing roles with Escalade, acquired by Mentor Graphics. Before that, Pete held several positions at LSI Logic. Pete has also served as a business strategy consultant for several companies.

Pete earned a bachelor's degree in electrical and computer engineering from the University of Wisconsin-Madison and an MBA from the University of Chicago.

Glen Donald, Director
Glen Donald has more than 30 years of sales, marketing, business development and management experience in technology-based companies. Previously, Glen was Vice President of Third Wave Technologies, Inc. (NASDAQ: TWTI) and General Manager of Third Wave's Agbio business. Prior to that Glen was Vice President of Marketing and member of the North American Management Team for Hoechst Agriculture Division. Glen earned a Bachelor of Science degree in Agriculture from the University of Saskatchewan.

Mike Treble, Co-founder & Director
Michael Treble was previously the Executive Chairman of Axela, Inc., a Toronto based venture firm operating in the field of proteomics for research and clinical markets.  He has served as a Board Member and Chairman since 2007.   Mr. Treble also served as the independent Director of GenturaDx which was acquired by Lumminix for $50 million in April, 2012.

Mr. Treble was the President and a Director of Ibis BioSciences, Inc., a subsidiary of Isis Pharmaceuticals., Inc. (NASDQ: ISIS), from December 2004 until January of 2009.  Ibis is a molecular infectious disease platform company which serves the research, forensics, bio-warfare and hospital markets.  Ibis was sold to Abbott Molecular in January 2008 for $215 million and a percentage of sales thru 2025.

Previously, Mr. Treble was President and CEO of NimbleGen Systems, Inc., from September 2000 thru March 2003.  NimbleGen is a genomics based company that developed desktop systems to produce high density, custom DNA arrays for academic, Bio-Pharm and Ag-bio applications.  NimbleGen was acquired by Roche for $272.5 million, in July 2007.  

Mr. Treble was also the Executive Vice President, Chief Operating Officer and Director of the Third Wave Technologies, Inc. (NASDQ: TWTI), a leader in the genomics field from July 1995 to July 2000.

Mr. Treble served as a Director of LUNA Analytics, a proteomics development company, Blacksburg, Virginia until December 2003 when the company's technology was licensed to Bio-Rad Laboratories.  

Mr. Treble was Chairman of the Board and a principal shareholder of Genetic Models, Inc., a supplier of genetically derived lab animals exhibiting human traits of hypertension and diabetes, which Mr. Treble co-founded in 1991. In 2001, Genetic Models was sold to Charles River Laboratories, Inc.

Prior to Mr. Treble's involvement in Genetic Models, Inc., he was an executive with A.M. Diagnostics, Inc (1987-1991), a publicly traded international analytical and clinical chemistry systems manufacturer, where he served as CEO (1990-1992). His prior positions include Director of Marketing and General Manager of Field Services for Roche Diagnostics and Marketing Manager for Abbott Diagnostics. Mr. Treble holds a Bachelor of Science degree from Canisius College and a Masters of Business Administration from the University of Buffalo.

Kirk Hogan, M.D., J.D., Co-founder

Dr. Hogan has received the following awards: the B.B. Sankey Anesthesia Advancement Award (International Anesthesia Research Society), the Foundation for Anesthesia Education and Research (FAER) Award, the Carl F. Koller Research Award (American Society of Regional Anesthesia), the Doris Duke Innovation in Clinical Research Award, the Anesthesia Patient Safety Foundation Anesthesia Healthcare Partners Award, Best Doctors in America, and the American Bar Association Bureau of National Affairs Award for Excellence in Intellectual Property. He has more than 100 research publications. He received a B.S. in Biology from UW-Madison, and both an M.D. and J.D. from UW-Madison. Dr. Hogan has been certified by the American Board of Anesthesiology, and is a registered U.S. patent attorney. His research focuses on pharmaco-epigenomics, and the effects of anesthesia, surgery and genetics on the onset and progression of Alzheimer’s disease.

Max Lagally, Ph.D., Co-founder
Max is a co-founder of SonoPlot and a co-inventor of the Company's fluid dispensing and plasma treatment technologies. He is also the Erwin W. Mueller Professor of Materials Science and Physics at the University of Wisconsin-Madison. In 1997 Max co-founded nPoint, Inc. (formerly PIEZOMAX Technologies, Inc.), a company that designs and manufactures high-precision nanopositioning devices and nanoprobes sold to the semiconductor, defense and research markets. Dr. Lagally is a fellow of the American Physical Society, the American Vacuum Society, the American Association for the Advancement of Science (AAAS), and the Australian Institute of Physics and a member of the German National Academy of Science Leopoldina and the National Academy of Engineering. The awards and honors he has received include the Medard W. Welch Award (American Vacuum Society), the David Adler Lectureship Award (American Physical Society), the Davisson-Germer Prize (American Physical Society), the MRS Medal (Materials Research Society), the Tibbetts Award, (SBA), the Humboldt Senior Research Fellowship (Forschungszentrum, Germany), and the Outstanding Science Alumnus Award, (Pennsylvania State University). He has more than 300 research publications, 3 patents, 6 patents pending or provisional patent applications, 8 disclosures, and is the editor or coeditor of 4 books. He has graduated 40 Ph.D. or M.S. students and currently advises 10 graduate students. Dr. Lagally received a B.S. in Physics from Pennsylvania State University and a Ph.D. in Solid-State Physics from the University of Wisconsin-Madison.